Skip to main content

Table 1 General characteristics of included systematic reviews

From: Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

Author, year

Country

Time frame

Search strategy/ Database

RCTs (n)

RCTs (n) included in our overview.

P

I

C

O

Funding

Conflicts of interest.

AMSTAR assessment

Iacovelli 2014 [23]

USA

From January 2004 to February 2014

Cochrane Central Register of Controlled Trials, MEDLINE, PubMed.

5

5

Gastric cancer

CT, Biological, or targeted therapy

BSC / Supportive care

Functional status, OS

No

None

CRITICALLY LOW

TerVeer 2016 [24]

Netherlands

Up to January 2016

Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE.

28

8

Esophageal, gastric, and GEJ cancer

CT, Biological, or targeted therapy

BSC / Placebo

OS, PFS, Toxicity

No

Yes

CRITICALLY LOW

Wang 2016 [25]

China

Up to December 31, 2015

Cochrane Library, EMBASE, PubMed

10

3

Gastric cancer

Biological or targeted therapy

Placebo

OS

Public

None

LOW

Chan a 2017 [26]

Australia

Up to December 2014

Cochrane Central Register of Controlled Trials, EMBASE, PubMed.

15

4

Gastric and GEJ cancer

Biological or targeted therapy

Placebo

OS, PFS, Toxicity, QoL

No

Yes

CRITICALLY LOW

Chan b 2017 [27]

China

Up to 2016

CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE

5

5

Gastric and GEJ cancer

CT, Biological, or targeted therapy

BSC / Placebo

OS, PFS, Toxicity

No

None

HIGH

Harvey 2017 [28]

UK

Between 1990 and 2015

PubMed, Scopus.

5

5

Gastric and GEJ cancer

CT

BSC

OS

NR

NR

CRITICALLY LOW

Janmaat 2017 [15]

Netherlands

Up to 13 May 2015

Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, Google Scholar, MEDLINE, PubMed, Web of Science, WHO International Clinical Trials Registry Platform (ICTRP)

41

5

Esophageal and GEJ cancer

CT, Biological, or targeted therapy

BSC / Placebo / Non-specified

OS

Public

None

HIGH

Wagner 2017 [29]

Switzerland

Up to June 2016

Cochrane Central Register of Controlled Trials, MEDLINE, Hand searched reference lists from studies, abstracts, conference.

64

3

Gastric and GEJ cancer

CT

BSC

OS

Public

Yes

HIGH

Wang 2017 [30]

China

Up to December 2015

Embase, Medline, the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE, MEDLINE

9

2

Gastric cancer

Biological or targeted therapy

Placebo

Toxicity

NR

None

MODERATE

Xie 2017 [31]

China

Between January 1st, 2000 and October 1st, 2016

Cochrane Library and Scopus, EMBASE,

23

2

Gastric and GEJ cancer

CT, Biological, or targeted therapy

Placebo

OS

NR

None

CRITICALLY LOW

Zhu 2017 [32]

Canada

Up to June 2014

American Society of Clinical Oncology abstracts, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE.

8

5

Gastric and GEJ cancer

CT, Biological, or targeted therapy

BSC / Placebo

OS

Private

Yes

CRITICALLY LOW

Liu 2018 [33]

China

Up to March 15, 2017

Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, EU Clinical Trials Register, Japan Pharmaceutical Information Center, PubMed.

8

4

Gastric and GEJ cancer

Biological or targeted therapy

Placebo

OS, PFS, Toxicity

Public / Private

None

LOW

Zhao 2018 [34]

China

Between 2002 and 2017

Cochrane Library, EMBASE, PubMed.

16

6

Esophageal, gastric and GEJ

Biological or targeted therapy

Placebo

OS, PFS, Toxicity

Public

None

CRITICALLY LOW

Chen 2019 [35]

China

Up to September 2018

PubMed

9

2

Gastric and GEJ cancer

Immunotherapy

BSC / Placebo

OS, PFS, Toxicity

Public

None

CRITICALLY LOW

van Kleef 2019 [36]

Netherlands

Up to April 2018

Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE.

43

8

Esophageal, gastric and GEJ

CT, Biological, or targeted therapy

BSC / Placebo

QoL

Public

Yes

CRITICALLY LOW

Wallis 2019 [37]

Canada

Up to October 2, 2018

EMBASE, MEDLINE, PubMed, Scopus.

23

1

Gastric and GEJ cancer

Immunotherapy

Placebo

OS

Private

Yes

CRITICALLY LOW

  1. GEJ gastroesophageal junction, P patients, I intervention, C comparator, O outcomes, CT chemotherapy, BSC best supportive care, OS overall survival, PFS progression-free survival, QoL quality of life, NR not reported